

## **Supplementary Information**

Identification of indocyanine green as a STT3B inhibitor against mushroom  $\alpha$ -amanitin cytotoxicity




Supplementary Figure 1. The gene hits from genome-wide CRISPR screen against AMA-induced cell death were enriched in the N-Glycan biosynthesis pathway. The counts of sgRNA of five significant genes,  $STT3B(\mathbf{a})$ ,  $MGAT1(\mathbf{b})$ ,  $ALG10(\mathbf{c})$ ,  $STT3A(\mathbf{d})$ , and  $RPN2(\mathbf{e})$ , on the N-Glycan biosynthesis pathway. The sgRNAs targeting the five genes were consistently enriched in AMA-treated cells. Source data are provided as a Source Data file.




Supplementary Figure 2. N-Glycan biosynthesis is essential for AMA-induced cell death. a-b Relative *STT3B* mRNA level in *STT3B* knockout HAP1 (a) and HepG2 (b) cells (n = 3 biological replicates). \*\*\*\*p < 0.0001. c WT and shSTT3B HepG2 cells were treated with vehicle or AMA for 72 h, and cell viability was determined by CCK8 assay (n = 3 biological replicates). d-e The combination of *STT3B* knockout and STT3A knockdown gave complete resistance to AMA in HepG2 cells. (d) The STT3A mRNA level of shSTT3A in sgSTT3B HepG2 cells (n = 3 biological replicates). \*\*\*p < 0.0001. (e) Knockdown of *STT3A* with *STT3B* knockout confers complete resistance to AMA (5 µM) in HepG2 cell lines (n = 6 biological replicates). \*\*\*p < 0.0001. f HAP1 cells were pre-treated with NGI for 12 h, and then treated with AMA (3 µM) for 48 h (n = 3


biological replicates). Data are presented as mean  $\pm$  S.D. and are representative of three independent experiments. The statistics were assessed using one-way ANOVA followed by Dunnett's multiple comparisons test. Source data are provided as a Source Data file.




Supplementary Figure 3. The calibration curve of AMA concentration (0.1-10  $\mu$ M) and peak area. The calibration curve showed a good linear relationship between AMA concentration (0.1-10  $\mu$ M) and peak area, with R<sup>2</sup> = 0.9999. Source data are provided as a Source Data file.



Supplementary Figure 4. The knockout of *STT3B* did not cause a significant change in ER and Golgi stress markers. Western blot analysis of stress response of ER (GRP78 and IRE1) and Golgi (GM130 and ARF4) in *STT3B* knockout cells. Source data are provided as a Source Data file.



Supplementary Figure 5. The effect of NGI-1 on disrupting N-linked glycosylation. ERLucT transfected HAP1 (a) and HepG2 (b) cells were treated with NGI-1 at 10  $\mu$ M and 20  $\mu$ M, respectively, and luciferase activity was measured (n = 3 biological replicates). \*\*\*\*p < 0.0001. The statistics were assessed using a two-tailed unpaired t test. Data are presented as mean  $\pm$  S.D. and are representative of three independent experiments. Source data are provided as a Source Data file.



Supplementary Figure 6. ICG is an effective antidote for AMA toxicity in mice. af Plasma levels of AST, ALT, ALP, INR, BUN, Cre in mice with different treatments (n = 6 biological replicates). (a)  ${}^{ns}p > 0.9999$ , \*\*\*\*p < 0.0001, \*\*\*p = 0.0005, \*\*p = 0.0067,  $^{ns}p = 0.7106, ^{ns}p = 0.9865;$  (b)  $^{ns}p > 0.9999, ^{***}p = 0.0002, ^{**}p = 0.0015, ^{**}p = 0.0095,$  $^{ns}p = 0.3460, ^{ns}p = 0.8754;$  (c)  $^{ns}p = 0.9999, ****p < 0.0001, **p = 0.0081, *p = 0.0341,$  $^{ns}p = 0.8868, ^{ns}p > 0.9999;$  (d)  $^{ns}p = 0.9984, ^{***}p = 0.0001, ^{*}p = 0.0149, ^{*}p = 0.0149,$  $^{ns}p = 0.9972$ ,  $^{ns}p = 0.9428$ ; (e)  $^{ns}p = 0.9999$ ,  $^{**}p = 0.0011$ ,  $^{ns}p = 0.2863$ ,  $^{ns}p = 0.6525$ ,  $^{ns}p = 0.7902$ ,  $^{ns}p = 0.8318$ ; (f)  $^{ns}p = 0.9993$ , \*\*p = 0.0072,  $^{ns}p = 0.1764$ ,  $^{ns}p = 0.4676$ ,  $^{ns}p = 0.9393$ ,  $^{ns}p > 0.9999$ . g-h H&E staining of liver and kidney in mice with different treatments. Cell degeneration (black arrow) and inflammatory cells (yellow arrow) were shown. Scale bars are 100 µm. i-l Pathological score of H&E staining of liver and kidney in different groups (n = 3 biological replicates). (i)  ${}^{ns}p > 0.9999$ , \*\*\*\*p < 0.0001, \*\*p = 0.0060, \*p = 0.0241, nsp = 0.9850, nsp > 0.9999; (j) nsp > 0.9999, nsp = 0.6423, nsp = 0.6= 0.9764,  $^{ns}p = 0.9764$ ,  $^{ns}p > 0.9999$ ,  $^{ns}p > 0.9999$ ; (k)  $^{ns}p > 0.9999$ ,  $^{ns}p = 0.0564$ ,  $^{ns}p = 0.056$  $0.2270, \ {}^{ns}p = 0.6423, \ {}^{ns}p = 0.9764, \ {}^{ns}p > 0.9999;$  (1)  ${}^{ns}p > 0.9999, \ {}^{ns}p = 0.9241, \ {}^{ns}p = 0.9$ 0.9241,  ${}^{ns}p = 0.9241$ ,  ${}^{ns}p > 0.9999$ ,  ${}^{ns}p > 0.9999$ . All data were represented as mean  $\pm$ S.D. The statistics were assessed using one-way ANOVA followed by Tukey's multiple comparisons test. Source data are provided as a Source Data file.

Primer sequences for amplifying sgRNA library	
Sense	TTGTGGAAAGGACGAAACACCG
Antisense	CCAATTCCCACTCCTTTCAAGACCT
sequences used for gene validation	
sgSTT3B#1	CCAGGGTTGATGATAACCGC
sgSTT3B#2	AAGAAAGACACCCAAGTCGT
sgNT	GGATCTAGCTACCTCAAAAG
shSTT3B#1-F	CCGGGCACTTCAGTTCACATACTATCTCGAGATAGTATGTGAACTGAAGTGCTTTTTG
shSTT3B#1-R	AATTCAAAAAGCACTTCAGTTCACATACTATCTCGAGATAGTATGTGAACTGAAGTGC
shSTT3B#2-F	CCGGGCAGTATCTGAGAGACCGATTCTCGAGAATCGGTCTCTCAGATACTGCTTTTTG
shSTT3B#2-R	AATTCAAAAAGCAGTATCTGAGAGACCGATTCTCGAGAATCGGTCTCTCAGATACTGC
shSTT3A-F	CCGGCGTCATAATACTCCAGAGGATCTCGAGATCCTCTGGAGTATTATGACGTTTTTG
shSTT3A-R	AATTCAAAAACGTCATAATACTCCAGAGGATCTCGAGATCCTCTGGAGTATTATGACG
Real-time RT-PCR primer	
STT3B-F	AGTAGGTGGTACTGTTTACCCAG
STT3B-R	AAGTTGGTGCAAGGAACACAC
STT3A-F	GAAGCAACAGGATTCCACCTACC
STT3A-R	CAATGGACGGAGAAGAGTAGGC
GAPDH-F	GGAGCGAGATCCCTCCAAAAT
GAPDH-R	GGCTGTTGTCATACTTCTCATGG

Supplementary Table 1. The various sequences used in this study.